Neurocrine Biosciences falls after halting development of schizophrenia drug

Neurocrine Biosciences

12/09/2024 22:01

** Shares of drugmaker Neurocrine Biosciences  NBIX.O  up
1.1% at $120 in after-hours trade
    ** Co to halt development of experimental drug, which did
not achieve primary goal in a mid-stage trial testing
    ** The drug, luvadaxistat, was being tested as a potential
treatment to improve cognitive function in patients with
schizophrenia
    ** NBIX says will focus resources on late-stage development
of other schizophrenia and depression drug candidates
    ** YTD, stock down 7.8% as of last close

 (Reporting by Juveria Tabassum in Bengaluru)
 ((Juveria.Tabassum@thomsonreuters.com))